A PROMISING ANTINEOPLASTIC DRUG – METFORMIN (AN AMPK ACTIVATOR) FOR THE FUTUREAbstract
Metformin, an AMPK activator, acts as an oral hypoglycaemic agent. It reduces the risk of cancer during the treatment of diabetes and diabetes associated cancers. The effect of metformin on different type of cancers is explained on the pathway of AMPK activation involving hepatic fatty acid oxidation, inhibition of triglyceride and cholesterol synthesis and also modulation of insulin secretion. There is evidence of reduced risk on cancer incidence and mortality in diabetic patients 13. The inverse association was significant for pancreatic and hepatocellular cancer and non-significant for colon, breast and prostate cancer. Metformin associated with a decreased risk of cancer incidence compared with other treatment among diabetic patients. The main process for reducing cancer risk in diabetic patients is the lowering of the uptake and utilisation of nutrients into the biomass needed to produce a new cell from an active proliferating cell. Many observational studies in favour of Metformin as an antineoplatic agent reported but the confirmed report may be forwarded in the near future.
Oinamjoychandra Singh, Indira Raleng, L. Surbala and N. Debashree *
Department of Pharmacology, JN Institute of Medical Sciences, Imphal, Manipur, India.
10 August, 2016
27 September, 2016
07 October, 2016
01 February, 2017